SecBot SecBot
PRESS-RELEASE ·Filed May 14, 2026

INKT

MiNK Therapeutics
BULLISH
Impact 7/10
Horizonmonths Processed6mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight ▲ Bullish

Traders should monitor for preliminary data in H2 2026, which could drive significant volatility. The prior Phase 1/2 data provides some de-risking, but the Phase 2 readout is the key catalyst. Given the $55M market cap, positive data could lead to a multi-bagger, while negative data could severely impair the stock. Consider position sizing accordingly.

DirectionBullish
Confidencemedium
Horizonmonths

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$10.51
T+0 close · May 14, 2026 · via day close
Latest settled
+4.19%
T+60 · $10.95
Vs SPY
+0.60%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 14 $10.51entry
  2. T+1 · 6mo ago +2.00%α +3.23% · $10.72
  3. T+5 · 6mo ago +4.09%α +4.81% · $10.94
  4. T+20 · 5mo ago +14.37%α +15.23% · $12.02
  5. T+60 · 3mo ago +4.19%α +0.60% · $10.95
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

MiNK Therapeutics announced the initiation of a randomized Phase 2 trial (C-1300-02) evaluating its off-the-shelf iNKT cell therapy agenT-797 in patients with acute lung injury and hypoxemic respiratory failure. The study, conducted in partnership with First Lviv Medical Union and UNBROKEN Ukraine, targets a large unmet need with no approved therapies, and preliminary data are expected in H2 2026. For a $55M market cap clinical-stage biotech, this represents a significant pipeline catalyst with potential to unlock a new indication beyond oncology.

Key Facts

  • Randomized Phase 2 trial (C-1300-02) initiated for agenT-797 in acute lung injury (ALI) with hypoxemic respiratory failure.
  • Study is placebo-controlled, evaluating survival, ventilator-free days, and secondary infections; preliminary data expected H2 2026.
  • AgenT-797 is an off-the-shelf allogeneic iNKT cell therapy, enabling rapid deployment in critical care without patient-specific manufacturing.
  • Prior Phase 1/2 data (Hammond et al., Nat Comms) showed improved survival and reduced secondary infections in virally induced ARDS.
  • Partnership with First Lviv Medical Union and UNBROKEN Ukraine provides access to a high-acuity patient population; U.S. sites being added.
  • ALI/ARDS affects ~200,000 patients annually in the U.S. with no approved mortality-reducing therapies.
  • MiNK market cap is ~$55M, making this a high-risk/high-reward catalyst for a small-cap biotech.

Financial Impact

No financial data provided; trial is early-stage with no revenue or deal value disclosed. Potential upside is binary based on H2 2026 data readout.

pipeline valuemarket capcash runway

Risk Factors

  • Clinical trial failure: Phase 2 may not replicate prior Phase 1/2 signals.
  • Regulatory uncertainty: No approved therapies exist for ARDS; path to approval is unproven.
  • Execution risk: Trial in Ukraine faces geopolitical and operational challenges.
  • Cash runway: As a clinical-stage company, MiNK may need to raise capital before data readout.
  • Competition: Other immune-modulating therapies in development for ARDS.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
88% bullish (8 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3294797

Track record

21 reports on INKT

Performance horizon

4 of 6 bullish or bearish reports moved the stock their way by T+20. Best: +16.93% at T+20 after the May 15, 2026 report. 4 of 6 went positive at some point.

Filters
  1. Nov 12, 20264d ago 8-K Neutral 4/10 Entry $9.53 Now $9.35 −1.89% settles Dec 11
  2. Nov 11, 20265d ago Press Release Neutral 4/10 Entry $10.22 Now $9.35 −8.55% settles Dec 10
  3. Nov 2, 202614d ago Press Release Neutral 2/10 Entry $10.79 Now $9.35 −13.35% settles Dec 2
  4. Oct 13, 20264w ago 144 Neutral 2/10 Entry $10.23 to $10.01 Now $9.35 −8.60% ▼ −2.15% +1.46% vs SPY
  5. Oct 2, 20266w ago Press Release Neutral 4/10 Entry $12.44 to $10.53 Now $9.35 −24.84% ▼ −15.35% −13.55% vs SPY
  6. Aug 13, 202613w ago 8-K Mixed 6/10 No price data
  7. Aug 13, 202613w ago Press Release Mixed 6/10 Entry $11.00 to $12.00 Now $9.35 −15.00% ▲ +9.09% +10.84% vs SPY
  8. Aug 6, 202614w ago Press Release Bullish 6/10 Entry $11.00 to $11.23 Now $9.35 −15.00% ▲ +2.09% +1.49% vs SPY
  9. May 28, 202624w ago Press Release Neutral 4/10 Entry $12.20 to $11.64 Now $9.35 −23.36% ▼ −4.59% −1.45% vs SPY
  10. May 20, 202625w ago Press Release Neutral 4/10 Entry $10.72 to $12.14 Now $9.35 −12.78% ▲ +13.25% +12.51% vs SPY
Showing 10 of 21

US Market Status

Market Closed · Opens Wed (10h 5m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 14, 2026